Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ECS BOTANICS HOLDINGS LTD Share Issue/Capital Change 2021

Jul 22, 2021

64818_rns_2021-07-22_134919af-f9fd-435b-a585-f269cd5706ed.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

ASX ANNOUNCEMENT

ECS Botanics Holdings Ltd (ASX:ECS)

23 July 2021

==> picture [103 x 105] intentionally omitted <==

Restricted Securities Released from Escrow

Pursuant to the announcement lodged by ECS Botanics Holdings Ltd (ASX: ECS) (“ECS” or the “Company”) with the ASX on 18 June 2021, an Appendix 2A application has been submitted for the quotation of 227,061,430 fully paid ordinary shares (Shares) that were released from escrow on 22 July 2021.

The Company also advises that 99,093,266 Performance Rights and 20,375,000 Unquoted Options (exercisable at $0.08 each, expiring 11 January 2022) have also been released from escrow.

The Performance Rights are not quoted and are convertible into fully paid ordinary shares, upon satisfaction of various vesting conditions (see Prospectus dated 10 May 2019) on a 1 for 1 basis.

  • The Company’s current capital structure (post escrow) is as follows:
CLASS Number
Fully paid ordinaryshares 862,980,667
Performance Rights 131,250,000
Unquoted Options (exercisable at $0.08 each, expiring11 January2022) 20,375,000

About ECS Botanics Holdings Ltd

ECS Botanics Holdings Ltd is a vertically integrated medicinal cannabis and industrial hemp business. The company owns farms and medicinal cannabis facilities in Tasmania and Victoria for the cultivation, processing, and manufacturing of medicinal cannabis. ECS manufactures to EU GMP standards and also has the necessary licences to cultivate and manufacture medicinal cannabis for the wholesale extract, final dose and premium dry flower market. ECS cultivates hemp for the wholesale market and its retail food and wellness brand, while having obtained all the necessary licences to grow, supply and manufacture. ECS’ core focus is scale and low-cost production, without compromising quality.

For further information, please contact: Alexander Keach, Managing Director [email protected]

Authorised on behalf of ECS by Alex Keach, Managing Director

==> picture [596 x 69] intentionally omitted <==